Gilead Sciences, Inc. and World Health Organization Establish New Five-Year Initiative to Prevent Deaths from Visceral Leishmaniasis

GENEVA--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it will donate 445,000 vials of AmBisome® (amphotericin B liposome for injection) over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar.